Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
2.
3.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
4.

Disposition of [14C]ruboxistaurin in humans.

Burkey JL, Campanale KM, Barbuch R, O'Bannon D, Rash J, Benson C, Small D.

Drug Metab Dispos. 2006 Nov;34(11):1909-17. Epub 2006 Aug 8.

PMID:
16896067
5.

Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Yeo KP, Lowe SL, Lim MT, Voelker JR, Burkey JL, Wise SD.

Br J Clin Pharmacol. 2006 Feb;61(2):200-10.

6.

In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.

Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, Kulanthaivel P.

Drug Metab Dispos. 2006 Feb;34(2):213-24. Epub 2005 Oct 28.

PMID:
16258078
7.

Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog.

Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, Farid NA.

Xenobiotica. 2002 Nov;32(11):1045-52.

PMID:
12487733
8.

Cytotoxicity and genotoxicity of methyleugenol and related congeners-- a mechanism of activation for methyleugenol.

Burkey JL, Sauer JM, McQueen CA, Sipes IG.

Mutat Res. 2000 Sep 20;453(1):25-33.

PMID:
11006409

Supplemental Content

Loading ...
Support Center